Eli Lilly & Co. Global External R&D-Asia VP Tony Zhang on Lilly's FIPNET Strategies In China: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
Eli Lilly, which launched its GLP-1 agonist Byetta (exenatide) in China in 2009, recently expanded its fully integrated pharmaceutical network (FIPNET) strategy by announcing that it would build up a diabetes-focused research center in Shanghai. Following the announcement, Tony Zhang, PhD, Lilly's global external R&D-Asia VP, sat down with PharmAsia News' Shanghai bureau along the sidelines of the BioPartnering China conference to talk about Lilly's evolving R&D strategy in Asia.
You may also be interested in...
Pfizer Sees Deeper Price Cuts, Lilly Maintains China Momentum – Emerging Market Earnings Roundup (Part 2)
Pfizer said that it has plans to rebound from a volatile fourth quarter of price cuts and slower than expected volume gains in emerging markets. Eli Lilly hopes to build on gains in China and boost volume growth overall in emerging markets to shore up revenues after major patents expired in key countries.
Emerging Markets Round Up From JP Morgan Healthcare Conference (Part 1 of 2)
Emerging markets took center stage among Big Pharma presentations at the annual JP Morgan Healthcare Conference in San Francisco last week.
Emerging Markets Round Up From JP Morgan Healthcare Conference (Part 1 of 2)
Emerging markets took center stage among Big Pharma presentations at the annual JP Morgan Healthcare Conference in San Francisco last week.